Eleva’s glyco-improved form of alpha Galactosidase - aGal (RPV-001) expressed in moss, has shown promising effects in a clinical Phase1b trial. Eleva’s proprietary aGal (RPV-001) exhibits superior cell uptake, prolonged efficacy and improved long-term safety. The recombinant aGal (RPV-001) program is a prime example for the positive impact of our proprietary expression system on key product capabilities otherwise unattainable with conventional production cell lines.